News & Events

For Immediate Release

Bookmark & Share
Contact: Kathryn Ryan, 914-740-2100, kryan@liebertpub.com
New Study Identifies Genetic Markers to Predict Sulfonylurea Effectiveness in Type 2 Diabetes

New Rochelle, NY, August 23, 2016—Researchers have identified variations in four genes involved in drug metabolism that, together with clinical factors, can help predict which patients with type 2 diabetes are more likely to benefit from the commonly prescribed drug sulfonylurea. The implications for using these genetic markers to predict drug response are discussed in an article in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until September 23, 2016.

Linong Ji, MD, Peking University People's Hospital (Beijing, People's Republic of China) and coauthors from Central South University (Changsha, P.R. China), and QIMR Berghofer Medical Research Institute (Brisbane, Australia), performed genetic analysis on patients with type 2 diabetes who participated in a clinical study to assess the safety and efficacy of sulfonylurea. They identified genetic variants associated with differences in sulfonylurea treatment response.

In the article “Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Type 2 Diabetic Subjects,” the researchers present the four genes containing variants that were significantly associated with improvement in HbA1c levels in the patients taking sulfonylurea. In predictive models, the addition of genetic markers to clinical factors alone improved the ability to predict sulfonylurea efficacy.

“Individualized treatment is the future for diabetes management as genetic differences might determine who will respond adequately to a glucose lowering agent,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver.

About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including ThyroidMetabolic Syndrome and Related DisordersJournal of Aerosol Medicine and Pulmonary Drug DeliveryChildhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News ), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.